aripiprazole has been researched along with Hyperprolactinaemia in 82 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 22 (26.83) | 29.6817 |
2010's | 45 (54.88) | 24.3611 |
2020's | 15 (18.29) | 2.80 |
Authors | Studies |
---|---|
Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
Chen, J; Chen, Y; Gao, L; Hao, C; Jin, J; Liu, BF; Liu, X; Ma, R; Wu, Q; Zhang, G; Zheng, L | 1 |
Kim, SG; Seo, EH; Yang, HJ; Yoon, HJ | 1 |
Chen, Y; Feng, X; Guo, L; Kang, Z; Liao, Y; Lu, Z; Sun, Y; Yue, W; Zhang, Y | 1 |
Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y | 1 |
Carlson, HE; Correll, CU; Kazimi, MM; Koch, MT | 1 |
Geracioti, TD; Strawn, JR | 1 |
Feng, X; Kang, Z; Liao, Y; Lu, T; Lu, Z; Sun, Y; Wang, L; Yan, H; Yue, W; Zhang, D; Zhang, Y | 1 |
Brand, BA; Hamers, IMH; Sommer, IE; Willemse, EJM | 1 |
Shad, MU; Yeager, A | 1 |
Abad-Santos, F; Koller, D | 1 |
Crespo-Facorro, B; García-Rizo, C; González-Rodríguez, A; Labad, J; Monreal, JA; Montalvo, I; Palao, D | 1 |
Besag, FMC; Salim, I; Vasey, MJ | 1 |
Alabbasi, AY; Nelson, LA; Rusgis, MM | 1 |
Bidollari, I; Claxton, A; Du, Y; Kelly, DL | 1 |
Shimoda, K; Shinozaki, M; Sugawara, N; Tasaki, M; Yasui-Furukori, N; Yokoyama, S | 1 |
Gunes, S | 1 |
Hall, W; Maneta, E; Mazher, OA | 1 |
Fryefield, K; Shad, MU | 1 |
Andreescu, N; Grădinaru, R; Nussbaum, L; Puiu, M; Suciu, L | 1 |
Liu, QS; Luo, T; Wei, B; Yang, YJ | 1 |
Medvedovici, A; Rădulescu, FŞ; Ranetti, AE; Voicu, V | 1 |
Bonete Llácer, JM; García Escudero, MA; Martínez Pastor, CJ; Ziadi Trives, M | 1 |
Li, X; Tang, Y; Wang, C | 1 |
Buchanan, RW; Dickerson, FB; Earl, AK; Feldman, S; Fischer, BA; Keller, WR; Kelly, DL; McMahon, RP; Shim, JC; Sullivan, KM; Warfel, D; Wehring, HJ | 1 |
Cavuto, M; De Berardis, D; Di Giannantonio, M; Fornaro, M; Girinelli, G; Iasevoli, F; Marini, S; Martinotti, G; Mazza, M; Perna, G; Piersanti, M; Serroni, N; Valchera, A | 1 |
Lozano, R; Marin, R; Santacruz, MJ | 1 |
Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W | 1 |
Glenmullen, J; Mattison, DR; Moore, TJ | 1 |
Bjelobaba, I; Budimirovic, DB; Kucka, M; Stojilkovic, SS; Tomić, M | 1 |
Bian, QT; Chen, JX; Correll, C; Liu, YH; Soares, JC; Su, YA; Wang, SL; Wei, LH; Yang, FD; Zhang, RZ; Zhang, XY | 1 |
Hu, LY; Hung, MB; Hung, YY; Lee, YT; Lu, T | 1 |
Ai, X; Ding, M; Ding, S; Gu, X; Huang, G; Li, X; Lv, L; Pang, L; Song, X; Zhao, J | 1 |
Baglivo, V; Balestrieri, M; Brambilla, P; Gregoraci, G; Isola, M; Meduri, M | 1 |
Culhane, C; Hope, J; Keks, NA | 1 |
Guo, Q; Li, C; Ouyang, Q; Qiao, Y; Shen, W; Sheng, J; Wen, H; Yang, F; Zhu, S | 1 |
Baymeeva, NV; Burminskiy, DS; Miroshnichenko, II; Morozova, MA; Platova, AI; Potanin, SS | 1 |
Badran, IA; Correll, CU; Curran, RL; DelBello, MP; Pedapati, EV; Peppers, V | 1 |
Hara, H; Kawashima, T; Kunitake, Y; Maruo, J; Minami, C; Mizoguchi, Y; Monji, A; Shimomura, Y; Sogawa, R | 1 |
Alphs, L; Correll, CU; Kim, E; Mao, L; Starr, HL | 1 |
An, FR; Chiu, HF; Jin, X; Li, L; Lok, GK; Ng, CH; Ungvari, GS; Wang, ZM; Wu, PP; Xiang, YT; Yang, R | 1 |
Aleksic, B; Banno, M; Fujioi, J; Iwamoto, K; Kikuchi, T; Ozaki, N | 1 |
Arango, C; Bernardo, M; Carrasco, JL; Crespo-Facorro, B; Cruz, JJ; Del Pino-Montes, J; García-Escudero, MA; García-Rizo, C; González-Pinto, A; Hernández, AI; Martín-Carrasco, M; Mayoral-Cleries, F; Mayoral-van Son, J; Montejo, ÁL; Mories, MT; Pachiarotti, I; Pérez, J; Ros, S; Vieta, E | 1 |
Abe, H; Funahashi, H; Ishida, Y; Naono, H; Naono-Nagatomo, K; Takeda, R; Uchimura, D | 1 |
Chen, CH; Lu, ML; Shen, WW | 1 |
Katsigiannopoulos, K; Kouvelas, D; Papazisis, G; Saitis, M | 1 |
Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R | 1 |
Bian, QT; Chen, JX; Haile, C; Kosten, TR; Liu, YH; Su, YA; Wang, N; Wang, SL; Yang, FD; Zhang, XY | 1 |
Capote, HA; Gengo, FM; Rainka, MM; Ross, CA | 1 |
Chen, ST; Hsiao, YL | 1 |
Albayrak, Y; Caykoylu, A; Ekinci, O; Kuloglu, M | 1 |
Deng, C; Huang, XF; Lian, J; Pai, N | 1 |
Manoj, P; Skopek, M | 1 |
Bae, KY; Kim, JM; Kim, SW; Shin, IS; Yang, SJ; Yoon, JS | 1 |
Hara, C; Ramos, MG; Rocha, FL | 1 |
Ishitobi, M; Kosaka, H; Murata, T; Shukunami, K; Wada, Y | 2 |
Chen, CK; Hsiao, CC; Huang, YS; Ree, SC | 1 |
Fujii, A; Furukori, H; Kaneko, S; Sugawara, N; Yasui-Furukori, N | 1 |
Lee, J; Ng, KW; Swapna, V | 1 |
Arends, J; Cohen, D; van Kooten, M | 1 |
Carlsson, A; Carlsson, ML; Johansson, AM; Rung, E; Rung, JP; Svensson, K | 1 |
Chou, J; Chung, MT; Lin, CH; Ma, H | 1 |
Chatziioannou, S; Filippopoulou, A; Lykouras, L; Peppa, M; Rizos, E; Tsigkaropoulou, E; Xelioti, I; Zompola, C | 1 |
Anandarajan, T; Bastiampillai, T; Dhillon, R; Tibrewal, P | 1 |
Mari, Jde J; Moreira, HC; Nunes, LV; Nunes, SO; Razzouk, D | 1 |
Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL | 1 |
Anghelescu, I; Wolf, J | 1 |
Citrome, L; Volavka, J | 1 |
Ostroff, R; Wahl, R | 1 |
Kim, YK; Lee, BH; Park, SH | 1 |
Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM | 1 |
Gründer, G; Paulzen, M | 1 |
Chen, CK; Lin, SK | 1 |
Fiedler, U; Wolf, J | 1 |
Kessler, RM | 1 |
Conley, RR; Jung, DU; Kelly, DL; Liu, KH; Seo, YS; Shim, JC; Shin, JG; Shon, JH | 1 |
Lorenz, RA; Weinstein, B | 1 |
Perlis, RH | 1 |
Chen, CH; Huang, MC; Lu, ML | 1 |
Aitchison, KJ; McAllister, V; Mir, A; O'Keane, V; Shivakumar, K; Williamson, RJ | 1 |
Hazra, M; Mamo, DC; Remington, G | 1 |
12 review(s) available for aripiprazole and Hyperprolactinaemia
Article | Year |
---|---|
Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Network Meta-Analysis; Prolactin; Vitamin B 6 | 2022 |
Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Estrogens; Female; Humans; Hyperprolactinemia; Male; Raloxifene Hydrochloride; Schizophrenia | 2023 |
Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Hyperprolactinemia; Prolactin; Psychotic Disorders | 2020 |
Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Prolactin; Psychotropic Drugs; Randomized Controlled Trials as Topic | 2021 |
Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Blood-Brain Barrier; Humans; Hyperprolactinemia; Isoxazoles; Paliperidone Palmitate; Piperazines; Prolactin; Pyrimidines; Quinolones; Receptors, Dopamine D2; Risperidone; Stress, Psychological; Sulpiride; Xenobiotics | 2013 |
Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Piperazines; Placebos; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Drug Partial Agonism; Drug Therapy, Combination; Humans; Hyperprolactinemia; Patents as Topic; Piperazines; Quinolones; Receptors, Dopamine D2 | 2014 |
A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorder; Child; Gastrointestinal Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Observational Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome; Weight Gain; Young Adult | 2016 |
Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Consensus; Humans; Hyperprolactinemia; Iatrogenic Disease; Mental Disorders | 2017 |
Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug Therapy, Combination; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Male; Piperazines; Psychotic Disorders; Purines; Quinolones; Schizophrenia; Schizophrenic Psychology; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2012 |
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Mental Disorders; Olanzapine; Patient Compliance; Piperazines; Practice Guidelines as Topic; Prescription Fees; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Thiazoles; Torsades de Pointes; Treatment Outcome; Weight Gain | 2004 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome; Weight Gain | 2007 |
13 trial(s) available for aripiprazole and Hyperprolactinaemia
Article | Year |
---|---|
Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Chemistry, Pharmaceutical; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Injections; Male; Middle Aged; Pilot Projects; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors; Treatment Outcome | 2013 |
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clinical Protocols; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Piperazines; Quinolones; Research Design; Schizophrenia | 2013 |
Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Blood Pressure; China; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hyperprolactinemia; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Weight Gain | 2014 |
Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Prolactin; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2015 |
Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Cholesterol; Drug Administration Schedule; Etoposide; Female; Humans; Hyperprolactinemia; Lipoproteins, HDL; Male; Mitoxantrone; Prednisone; Prolactin; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides; Vincristine | 2015 |
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Delayed-Action Preparations; Female; Haloperidol; Humans; Hyperprolactinemia; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Perphenazine; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Failure; Treatment Outcome | 2016 |
Effect of Adjunctive Aripiprazole on Sexual Dysfunction in Schizophrenia: A Preliminary Open-Label Study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Male; Prolactin; Schizophrenia; Sexual Dysfunction, Physiological | 2017 |
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Sulpiride; Young Adult | 2008 |
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Sex Factors; Substance Withdrawal Syndrome; Young Adult | 2009 |
Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Size; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Female; Hip; Humans; Hyperprolactinemia; Liver Function Tests; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Thiazoles; Treatment Outcome; Waist Circumference; Wakefulness; Young Adult | 2010 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Hyperprolactinemia; Long QT Syndrome; Male; Piperazines; Placebos; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2002 |
Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Aged; Pilot Projects; Piperazines; Prolactin; Quinolones; Schizophrenia; Time Factors | 2006 |
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Dopamine Antagonists; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Placebos; Quinolones; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Sex Factors; Treatment Outcome | 2007 |
57 other study(ies) available for aripiprazole and Hyperprolactinaemia
Article | Year |
---|---|
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition; Dopamine; Drug Design; Humans; Hyperprolactinemia; Mice; Models, Animal; Movement; Piperidines; Protein Binding; Receptors, Histamine H3; Risperidone; Serotonin; Structure-Activity Relationship; Weight Gain | 2021 |
Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benztropine; Female; Humans; Hyperprolactinemia; Prolactin; Propranolol; Psychomotor Agitation; Psychotic Disorders; Young Adult | 2022 |
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones; Recurrence; Schizophrenia | 2023 |
Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Erectile Dysfunction; Female; Galactorrhea; Humans; Hyperprolactinemia; Male; Mentally Ill Persons; Olanzapine; Pregnancy; Prolactin; Prospective Studies; Quetiapine Fumarate; Risperidone | 2023 |
Editorial: A Better Perspective on Antipsychotic-Related Hyperprolactinemia in Children and Adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Dopamine; Female; Humans; Hyperprolactinemia; Male; Prolactin; Risperidone | 2023 |
Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: Randomized clinical trials and multi-ancestry validation.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Lipids; Olanzapine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2023 |
Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia A Retrospective Case Series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Middle Aged; Prolactin; Psychotic Disorders; Retrospective Studies; Schizophrenia | 2020 |
The pharmacogenetics of aripiprazole-induced hyperprolactinemia: what do we know?
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Pharmacogenetics; Receptors, Dopamine; Receptors, Serotonin | 2020 |
Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Mental Disorders; Prolactin | 2021 |
Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Male; Paliperidone Palmitate; Prolactin; Prospective Studies; Schizophrenia | 2021 |
Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels.
Topics: Antipsychotic Agents; Aripiprazole; Female; Genetic Diseases, Inborn; Humans; Hyperprolactinemia; Lactation Disorders; Male; Paliperidone Palmitate; Prolactin; Risperidone; Schizophrenia; Testosterone | 2021 |
Hyperprolactinemic Galactorrhea as a Side Effect of Aripiprazole: An Adolescent Case (Aripiprazole-Related Hyperprolactinemic Galactorrhea).
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Aripiprazole; Female; Galactorrhea; Humans; Hyperprolactinemia; Mood Disorders | 2018 |
Treatment of Risperidone-Associated Hyperprolactinemia With Aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Risperidone | 2018 |
Can low-dose aripiprazole reverse some of the adverse effects from a long-acting injectable?
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Hyperprolactinemia; Injections; Psychotic Disorders | 2019 |
Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients.
Topics: Adolescent; Alleles; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Cytochrome P-450 CYP2D6; Female; Humans; Hyperprolactinemia; Male; Phenotype; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Young Adult | 2019 |
Aripiprazole for the treatment of duloxetine-induced hyperprolactinemia: A case report.
Topics: Adolescent; Amenorrhea; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Galactorrhea; Humans; Hyperprolactinemia; Menstruation Disturbances; Prolactin; Receptors, Dopamine D2 | 2019 |
Prolactin deficiency by aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Genetic Diseases, Inborn; Humans; Hyperprolactinemia; Lactation Disorders; Piperazines; Prolactin; Quinolones | 2014 |
Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs.
Topics: Adult; Aged; Aripiprazole; Benzothiazoles; Compulsive Behavior; Consumer Behavior; Dopamine Agonists; Drug Labeling; Female; Gambling; Humans; Hyperprolactinemia; Impulsive Behavior; Indoles; Male; Middle Aged; Parkinson Disease; Piperazines; Pramipexole; Quinolones; Receptors, Dopamine D3; Restless Legs Syndrome; Retrospective Studies; Sexual Behavior; United States; United States Food and Drug Administration | 2014 |
Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs.
Topics: Animals; Aripiprazole; Calcium Signaling; Dopamine; Female; Humans; Hyperprolactinemia; Lactotrophs; Paliperidone Palmitate; Prolactin; Rats; Schizophrenia; Signal Transduction | 2015 |
Using aripiprazole to treat new-onset hyperprolactinemia-related delusion of pregnancy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Hyperprolactinemia; Risperidone; Schizophrenia | 2015 |
Aripiprazole long-acting injection: promising but more evidence needed.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Injections, Intramuscular; Schizophrenia; Weight Gain | 2016 |
Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Estradiol; Female; Humans; Hyperprolactinemia; Middle Aged; Paliperidone Palmitate; Prolactin; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2016 |
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Depression; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Prolactin; Risperidone; Schizophrenia; Schizophrenic Psychology; Young Adult | 2015 |
Aripiprazole for the Treatment of Antipsychotic-Induced Hyperprolactinemia in an Adolescent Boy.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Hyperprolactinemia; Male; Prolactin; Quinolones; Schizophrenia | 2016 |
Aripiprazole-Associated Hypoprolactinemia in the Clinical Setting.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Prolactin; Retrospective Studies | 2016 |
Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Case-Control Studies; China; Clozapine; Female; Humans; Hyperprolactinemia; Male; Mental Disorders; Quality of Life; Risperidone; Sexual Dysfunction, Physiological; Young Adult | 2016 |
Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Japan; Male; Middle Aged; Prolactin; Schizophrenia; Treatment Outcome | 2017 |
Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Long-Term Care; Piperazines; Quinolones; Schizophrenia, Paranoid; Sulpiride; Thiazoles; Young Adult | 2008 |
Aripiprazole treatment of risperidone-induced hyperprolactinemia.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia | 2009 |
Attenuation of risperidone-induced hyperprolactinemia with the addition of aripiprazole.
Topics: Aripiprazole; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Quinolones; Receptors, Dopamine D2; Risperidone | 2009 |
Treatment with aripiprazole for hyperprolactinemia induced by pituitary microadenoma in a bipolar I disorder patient.
Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Pituitary Neoplasms; Quinolones | 2010 |
Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Antagonists; Drug Substitution; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Secondary Prevention | 2010 |
Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Hyperprolactinemia; Obesity; Piperazines; Quinolones; Schizophrenia | 2010 |
Hyperprolactinaemia during treatment with paliperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Galactorrhea; Humans; Hyperprolactinemia; Isoxazoles; Middle Aged; Paliperidone Palmitate; Patient Compliance; Piperazines; Prolactin; Psychotic Disorders; Pyrimidines; Quetiapine Fumarate; Quinolones; Recurrence; Schizophrenia, Paranoid; Young Adult | 2010 |
Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Isoxazoles; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia, Paranoid; Treatment Outcome | 2010 |
Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Piperidines; Quinolones; Schizophrenia | 2010 |
Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzamides; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Prolactin; Prospective Studies; Quinolones; Risperidone; Young Adult | 2010 |
Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
Topics: Adult; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Prolactin; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2010 |
Management of a patient with schizophrenia and underlying pituitary macroadenoma.
Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bromocriptine; Dopamine Antagonists; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Pituitary Neoplasms; Quinolones; Risperidone; Schizophrenia; Serotonin Antagonists; Trifluoperazine | 2010 |
Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection.
Topics: Adult; Aripiprazole; Delayed-Action Preparations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Injections; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia | 2011 |
Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
Topics: Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Piperazines; Quinolones; Risperidone; Schizophrenia | 2011 |
Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.
Topics: Animals; Aripiprazole; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Haloperidol; Hyperprolactinemia; Lactotrophs; Male; Methyltyrosines; Piperazines; Piperidines; Prolactin; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Reserpine | 2011 |
Granulomatous cutaneous lesions associated with risperidone-induced hyperprolactinemia in an amputated upper limb.
Topics: Amputation Stumps; Antipsychotic Agents; Aripiprazole; Forearm; Granuloma; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Quinolones; Risperidone; Schizophrenia; Skin Diseases; Treatment Outcome | 2012 |
Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cabergoline; Ergolines; Humans; Hyperprolactinemia; Hypogonadism; Male; Obesity, Morbid; Piperazines; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychotic Disorders; Quinolones; Schizophrenia | 2012 |
Hyperprolactinaemia on depot risperidone treated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Monitoring; Drug Substitution; Female; Humans; Hyperprolactinemia; Medication Therapy Management; Pharmacovigilance; Piperazines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2012 |
Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Piperazines; Prolactin; Quinolones; Schizophrenia, Paranoid; Sexual Dysfunctions, Psychological; Thiazoles | 2004 |
Reversal of symptomatic hyperprolactinemia by aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Injections, Intramuscular; Piperazines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2005 |
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Female; Galactorrhea; Gynecomastia; Haloperidol; Humans; Hyperprolactinemia; Male; Olanzapine; Piperazines; Pituitary Neoplasms; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Sex Factors; Thiazoles; United States; United States Food and Drug Administration | 2006 |
Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Middle Aged; Piperazines; Quinolones; Schizophrenia; Sulpiride; Treatment Failure | 2007 |
Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Hyperprolactinemia; Obesity; Piperazines; Quinolones; Risperidone; Schizophrenia, Paranoid; Treatment Outcome; Weight Gain | 2006 |
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones | 2007 |
Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Synaptic Transmission | 2007 |
Resolution of haloperidol-induced hyperprolactinemia with aripiprazole.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clonazepam; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gynecomastia; Haloperidol; Humans; Hyperprolactinemia; Male; Piperazines; Prolactin; Quinolones; Valproic Acid | 2007 |
Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Male; Piperazines; Quinolones; Schizophrenia; Sulpiride | 2008 |
Change in sexual dysfunction with aripiprazole: a switching or add-on study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Ejaculation; Erectile Dysfunction; Female; Humans; Hyperprolactinemia; Libido; Male; Menstruation Disturbances; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Sex Characteristics; Sexual Dysfunction, Physiological; Surveys and Questionnaires | 2008 |
Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Polypharmacy; Quinolones; Schizophrenia | 2008 |